US commenters warn of ‘unintended consequences’ in pharma patent crackdown

US commenters warn of ‘unintended consequences’ in pharma patent crackdown

Potential initiatives to limit continuation practice are causing deep divides in the life sciences patent community – causing technology licensors and Big Tech to take sides

Unlock unlimited access to all IAM content